Literature DB >> 12622342

The neuropsychological test performance of drug-abusing patients: an examination of latent cognitive abilities and associated risk factors.

William Fals-Stewart1, Marsha E Bates.   

Abstract

The purpose of this study was to examine the latent structure of neuropsychological abilities of drug-abusing patients. Four factors were identified in an exploratory factor analysis (N = 329) and a subsequent confirmatory factor analysis (N = 258): Executive Functioning, Verbal Ability, Memory, and Speed, Education, years of regular alcohol use, number of substance use dependence disorders, percentage of days of heavy drinking in the previous year, depression, familial alcoholism, premorbid level of cognitive functioning, liver functioning, and previous head injuries were identified as risk factors to these latent abilities.

Entities:  

Mesh:

Year:  2003        PMID: 12622342     DOI: 10.1037//1064-1297.11.1.34

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  17 in total

1.  Profiles of executive functioning: associations with substance dependence and risky sexual behavior.

Authors:  Sarit A Golub; Tyrel J Starks; William J Kowalczyk; Louisa I Thompson; Jeffrey T Parsons
Journal:  Psychol Addict Behav       Date:  2012-07-09

2.  The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina.

Authors:  Kimber L Price; Stacia M DeSantis; Annie N Simpson; Bryan K Tolliver; Aimee L McRae-Clark; Michael E Saladin; Nathaniel L Baker; Mark T Wagner; Kathleen T Brady
Journal:  Am J Addict       Date:  2011-07-18

3.  Relative Importance of Emotional Dysregulation, Hostility, and Impulsiveness in Predicting Intimate Partner Violence Perpetrated by Men in Alcohol Treatment.

Authors:  Andra Teten Tharp; Julie A Schumacher; Alison C McLeish; Rita E Samper; Scott F Coffey
Journal:  Psychol Women Q       Date:  2012-03-01

4.  Risk factors and neuropsychological recovery in clients with alcohol use disorders who were exposed to different treatments.

Authors:  Marsha E Bates; Danielle Barry; Erich W Labouvie; William Fals-Stewart; Gerald Voelbel; Jennifer F Buckman
Journal:  J Consult Clin Psychol       Date:  2004-12

5.  Alcohol use biomarkers predicting cognitive performance: a secondary analysis in veterans with alcohol dependence and posttraumatic stress disorder.

Authors:  Raj K Kalapatapu; Kevin L Delucchi; Brooke A Lasher; Sophia Vinogradov; Steven L Batki
Journal:  Mil Med       Date:  2013-09       Impact factor: 1.437

6.  Specificity of executive functioning and processing speed problems in common psychopathology.

Authors:  Joel T Nigg; Jennifer M Jester; Gillian M Stavro; Ka I Ip; Leon I Puttler; Robert A Zucker
Journal:  Neuropsychology       Date:  2017-01-16       Impact factor: 3.295

Review 7.  Cognitive function as an emerging treatment target for marijuana addiction.

Authors:  Mehmet Sofuoglu; Dawn E Sugarman; Kathleen M Carroll
Journal:  Exp Clin Psychopharmacol       Date:  2010-04       Impact factor: 3.157

8.  Self-reported cognitive scales in a US National Survey: reliability, validity, and preliminary evidence for associations with alcohol and drug use.

Authors:  Efrat Aharonovich; Dvora Shmulewitz; Melanie M Wall; Bridget F Grant; Deborah S Hasin
Journal:  Addiction       Date:  2017-07-31       Impact factor: 6.526

9.  Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT.

Authors:  Kathleen M Carroll; Samuel A Ball; Steve Martino; Charla Nich; Theresa A Babuscio; Kathryn F Nuro; Melissa A Gordon; Galina A Portnoy; Bruce J Rounsaville
Journal:  Am J Psychiatry       Date:  2008-05-01       Impact factor: 18.112

10.  Validity of cognitive complaints in substance-abusing patients and non-clinical controls: the Patient's Assessment of Own Functioning Inventory (PAOFI).

Authors:  Randall Richardson-Vejlgaard; Sharron Dawes; Robert K Heaton; Morris D Bell
Journal:  Psychiatry Res       Date:  2009-07-19       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.